Evidence map›Paper›PMID 26098795›Full record

ArticleBiochemistry2015

Huntingtin N-Terminal Monomeric and Multimeric Structures Destabilized by Covalent Modification of Heteroatomic Residues.

James R Arndt, Samaneh Ghassabi Kondalaji, Megan M Maurer, Arlo Parker, Justin Legleiter, Stephen J Valentine

Abstract read
In one paragraph

Article in Biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Cholesterol impacts the formation of huntingtin/lipid complexes and subsequent aggregation.Protein science : a publication of the Protein Society · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Lipid headgroups alter huntingtin aggregation on membranes.Biochimica et biophysica acta. Biomembranes · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James R Arndt†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
Samaneh Ghassabi Kondalaji†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
Megan M Maurer†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
Arlo Parker†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
Justin Legleiter†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
Stephen J Valentine†C. Eugene Bennett Department of Chemistry, ‡WVNano Safe Initiative, and §The Center for Neuroscience, West Virginia University, Morgantown, West Virginia 26506, United States.
West Virginia University · US

Funding

Factors modulating the interaction of huntingtin with lipid membranes: Implications for Huntington's DiseaseR15NS090380 · NINDS · WEST VIRGINIA UNIVERSITY · PI LEGLEITER, JUSTIN · 2014 to 2014
$448k
NINDS NIH HHS R15 NS090380NINDS NIH HHS R15NS090380
6 · The paper itself

Abstract

Early stage oligomer formation of the huntingtin protein may be driven by self-association of the 17-residue amphipathic α-helix at the protein's N-terminus (Nt17). Oligomeric structures have been implicated in neuronal toxicity and may represent important neurotoxic species in Huntington's disease. Therefore, a residue-specific structural characterization of Nt17 is crucial to understanding and potentially inhibiting oligomer formation. Native electrospray ion mobility spectrometry-mass spectrometry (IMS-MS) techniques and molecular dynamics simulations (MDS) have been applied to study coexisting monomer and multimer conformations of Nt17, independent of the remainder of huntingtin exon 1. MDS suggests gas-phase monomer ion structures comprise a helix-turn-coil configuration and a helix-extended-coil region. Elongated dimer species comprise partially helical monomers arranged in an antiparallel geometry. This stacked helical bundle may represent the earliest stages of Nt17-driven oligomer formation. Nt17 monomers and multimers have been further probed using diethylpyrocarbonate (DEPC). An N-terminal site (N-terminus of Threonine-3) and Lysine-6 are modified at higher DEPC concentrations, which led to the formation of an intermediate monomer structure. These modifications resulted in decreased extended monomer ion conformers, as well as a reduction in multimer formation. From the MDS experiments for the dimer ions, Lys6 residues in both monomer constituents interact with Ser16 and Glu12 residues on adjacent peptides; therefore, the decrease in multimer formation could result from disruption of these or similar interactions. This work provides a structurally selective model from which to study Nt17 self-association and provides critical insight toward Nt17 multimerization and, possibly, the early stages of huntingtin exon 1 aggregation.

Indexed as

Diethyl PyrocarbonateHumansHuntingtin ProteinLysineMass SpectrometryMolecular Dynamics SimulationNerve Tissue ProteinsPeptidesProtein ConformationProtein MultimerizationProtein StabilityProtein Structure, SecondaryThreonineDiethyl PyrocarbonateHTT protein, humanHuntingtin ProteinLysineNerve Tissue ProteinsPeptidesThreonine

Identifiers

PMID26098795
PMCPMC4617767
OpenAlexW757827641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.